logo
logo
Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.

NASDAQ•AMRX
CEO: Mr. Chirag K. Patel
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2018-05-07
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
連絡先情報
400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, 08807, United States
908-947-3120
amneal.com
時価総額
$4.66B
PER (TTM)
789.1
36.6
配当利回り
--
52週高値
$15.00
52週安値
$6.69
52週レンジ
98%
順位55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$784.51M+11.68%
直近4四半期の推移

EPS

$0.01-1600.00%
直近4四半期の推移

フリーCF

$103.40M-14.59%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Growth Net revenue for nine months reached $2.20B USD, marking a 6.8% increase year-over-year period.
Operating Income Surge Operating income grew substantially to $282.1M USD for nine months, increasing by 62.5% from prior year.
Profitability Turnaround Achieved Swung to Net Income of $78.4M USD for nine months, reversing prior year net loss position.
Strong Cash Flow Generation Net cash provided by operating activities was $209.7M USD for nine months, up 18.4%.

リスク要因

Intangible Asset Impairment Recorded $22.8M intangible asset impairment charge in cost of goods sold for nine months period.
Opioid Litigation Liability Opioid litigation liability remains significant at $114.1M as of September 30, 2025, subject to finalization.
Quarterly Gross Margin Pressure Quarterly gross profit margin decreased to 34.9% due to higher cost of goods sold and impairments.
Government Shutdown Risk Government shutdown risk threatens timely FDA interactions, potentially impacting regulatory approvals and operations.

見通し

Major Debt Refinancing Complete Completed major refinancing in August 2025, securing $2.1B Term Loan Due 2032 and new notes.
Capital Expenditure Investment Expecting approximately $120.0M capital expenditures during 2025 for manufacturing equipment and IT growth.
Opioid Settlement Funding Deposited $24.2M restricted cash towards finalizing nationwide opioid settlement agreement terms.

同業比較

売上高 (TTM)

Bausch Health Companies Inc.BHC
$10.03B
+5.9%
Perrigo Company plcPRGO
$4.28B
-2.5%
Amneal Pharmaceuticals, Inc.AMRX
$2.93B
+9.5%

粗利益率 (最新四半期)

Soleno Therapeutics, Inc.SLNO
98.3%
+0.0pp
Mirum Pharmaceuticals, Inc.MIRM
80.8%
+3.8pp
Supernus Pharmaceuticals, Inc.SUPN
74.8%
-15.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
MIRM$5.33B-144.6-16.5%40.6%
NVST$4.76B101.31.5%28.1%
LNTH$4.72B27.814.8%27.2%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.4%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月27日
|
EPS:$0.17
|
売上高:$806.07M
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $784.51M+11.7%
    |
    EPS: $0.01-1600.0%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $724.51M+3.2%
    |
    EPS: $0.07+268.0%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $695.42M+5.5%
    |
    EPS: $0.04-113.1%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月28日|
    売上高: $2.79B+16.7%
    |
    EPS: $-0.38+20.8%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月12日|
    売上高: $702.47M+13.3%
    |
    EPS: $-0.00-100.8%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月9日|
    売上高: $701.78M+17.2%
    |
    EPS: $0.02-75.8%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月8日|
    売上高: $659.19M+18.2%
    |
    EPS: $-0.30+351.8%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月14日|
    売上高: $2.39B+8.2%
    |
    EPS: $-0.48+44.2%
    予想を下回る